Should you buy Lantheus Holdings (LNTH)?
Updated
Lantheus Holdings operates a high-quality specialty healthcare franchise with exceptional free cash flow conversion and a perfect financial health score, but the stock has moved above its near-term price target, leaving the risk/reward firmly negative at the current price.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow conversion stands at 151% of net income, the business earns strong 18% margins, and the Piotroski financial health score is a perfect 9 out of 9 — hallmarks of a franchise that reliably turns reported earnings into real cash. Quality breakdown | Free cash flow conversion remains above 100% of net income and operating margins hold above 15% over the next 12 months. | →Stable |
| CounterSole-supplier dependence on synthesis boxes and a proprietary lipid blend creates single-point-of-failure risk; a disruption to either relationship could impair production and compress the very margins that underpin this quality assessment. | ||
The stock trades at a forward price-to-earnings multiple of 16.4 times with a price-to-earnings-to-growth ratio of 0.21, suggesting the market is not fully pricing in the earnings growth trajectory relative to peers. Valuation breakdown | Forward earnings estimates hold or rise, keeping the PEG below 0.5 over the next 12 months. | →Stable |
| CounterThe stock has already moved above its near-term price target, suggesting the market may have already reflected medium-term growth expectations; any deceleration in earnings could quickly eliminate the apparent valuation cushion. | ||
The two most recent quarters each beat analyst consensus — the latest by roughly 19% and the one before by nearly 43% — suggesting the company has been delivering ahead of expectations in its most recent earnings cycle. Earnings | EPS beats analyst consensus in each of the next two reported quarters, extending the recent outperformance pattern. | →Stable |
| CounterBefore these two beats, the company delivered one in-line result and, prior to that, a miss — a four-quarter history that is too mixed to characterize as a durable pattern of guidance discipline. | ||
Free cash flow conversion stands at 151% of net income, the business earns strong 18% margins, and the Piotroski financial health score is a perfect 9 out of 9 — hallmarks of a franchise that reliably turns reported earnings into real cash.
→Stable- Expectation
- Free cash flow conversion remains above 100% of net income and operating margins hold above 15% over the next 12 months.
CounterSole-supplier dependence on synthesis boxes and a proprietary lipid blend creates single-point-of-failure risk; a disruption to either relationship could impair production and compress the very margins that underpin this quality assessment.
The stock trades at a forward price-to-earnings multiple of 16.4 times with a price-to-earnings-to-growth ratio of 0.21, suggesting the market is not fully pricing in the earnings growth trajectory relative to peers.
→Stable- Expectation
- Forward earnings estimates hold or rise, keeping the PEG below 0.5 over the next 12 months.
CounterThe stock has already moved above its near-term price target, suggesting the market may have already reflected medium-term growth expectations; any deceleration in earnings could quickly eliminate the apparent valuation cushion.
The two most recent quarters each beat analyst consensus — the latest by roughly 19% and the one before by nearly 43% — suggesting the company has been delivering ahead of expectations in its most recent earnings cycle.
→Stable- Expectation
- EPS beats analyst consensus in each of the next two reported quarters, extending the recent outperformance pattern.
CounterBefore these two beats, the company delivered one in-line result and, prior to that, a miss — a four-quarter history that is too mixed to characterize as a durable pattern of guidance discipline.
▸ Show 1 more pillar▾ Show fewer
Reliance on sole suppliers for both synthesis boxes and the proprietary lipid blend exposes the business to concentrated supply-chain risk that could disrupt production or elevate costs if either relationship is impaired.
→Stable- Expectation
- The company discloses a second qualified supplier for at least one of the sole-sourced inputs within 12 months, reducing single-supplier exposure.
CounterLong-standing sole-supplier relationships may reflect proprietary technology lock-in that competitors cannot easily replicate, creating a form of exclusive supply access that functions as a barrier to entry rather than pure vulnerability.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Free cash flow conversion stands at 151% of net income, the business earns strong 18% margins, and the Piotroski financial health score is a perfect 9 out of 9 — hallmarks of a franchise that reliably turns reported earnings into real cash.
Trip ifFree cash flow conversion falls below 80% of net income for 2 consecutive quarters.
- P2The two most recent quarters each beat analyst consensus — the latest by roughly 19% and the one before by nearly 43% — suggesting the company has been delivering ahead of expectations in its most recent earnings cycle.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P3The stock trades at a forward price-to-earnings multiple of 16.4 times with a price-to-earnings-to-growth ratio of 0.21, suggesting the market is not fully pricing in the earnings growth trajectory relative to peers.
Trip ifForward P/E expands above 25x without a corresponding increase in earnings estimates.
- P4Reliance on sole suppliers for both synthesis boxes and the proprietary lipid blend exposes the business to concentrated supply-chain risk that could disrupt production or elevate costs if either relationship is impaired.
Trip ifManagement discloses a supply disruption from either sole supplier affecting more than 30 days of production.
How the engine reached this verdict
TrendMatrix's engine output for Lantheus Holdings, Inc. (LNTH) is HOLD_IF_HOLDING with medium conviction, score 5.7/10 at $106.61. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
On the bull side: High-quality business. On the bear side: Concentration risk — Supplier: sole suppliers (synthesis boxes, lipid blend); Analyst target reached - limited upside remaining; Near 52-week high (1.2% away). Active engine warnings: V8: Target reached (-14.2% upside), V9 Gate Failed: MOMENTUM:3.3<4.5, V9 Gate Failed: ASYMMETRY:-1.3=NEGATIVE.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $100.56 for existing positions. Asymmetric R:R is -0.14, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
HOLD flips toward BUY_WAIT if momentum at 3.3 vs threshold 4.5 clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates LNTH — 10-dimension breakdown →
Bull case
- ▸High-quality business
Bear case
- ▸Concentration risk — Supplier: sole suppliers (synthesis boxes, lipid blend)
- ▸Analyst target reached - limited upside remaining
- ▸Near 52-week high (1.2% away)